Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemigatinib - Incyte Corporation

Next Previous
Drug Profile

Pemigatinib - Incyte Corporation

Alternative Names: IBI-375; INCB 54828; INCB-054828; Pemazyre

Latest Information Update: 17 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Academic and Community Cancer Research United; Incyte Biosciences International; Incyte Corporation; Innovent Biologics; Knight Therapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Ethers; Fluorobenzenes; Morpholines; Pyridines; Pyrimidinones; Pyrroles; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Myeloproliferative disorders; Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholangiocarcinoma
  • Registered Lymphoma; Myeloproliferative disorders
  • Phase II Adenosquamous carcinoma; Bladder cancer; Colorectal cancer; Endometrial cancer; Glioblastoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase I/II Cancer

Most Recent Events

  • 06 Nov 2025 Launched for Cholangiocarcinoma (Second-line therapy or greater, In adults, Metastatic disease, Late-stage disease) in Mexico (PO), before November 2205
  • 05 Nov 2025 Launched for Cholangiocarcinoma (In adults, Second-line therapy or greater, Metastatic disease, Late-stage disease) in Brazil (PO), before November 2205
  • 05 Nov 2025 Registered for Cholangiocarcinoma (In adults, Second-line therapy or greater, Metastatic disease, Late-stage disease) in Brazil (PO), before November 2205

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top